What Does KRA Mean on a Drug Test?

KRA is the abbreviation for kratom on a drug test panel. It signals that the test is specifically screening for mitragynine, the primary active alkaloid in the tropical plant Mitragyna speciosa, commonly sold as kratom. Because kratom is not included in standard five- or ten-panel workplace drug screens, seeing “KRA” means someone ordered an expanded or specialized panel that targets it deliberately. The fact that a separate code exists for kratom reflects its unusual regulatory status and the growing demand for ways to detect it.

Why Kratom Has Its Own Panel Code

Standard urine drug tests used for most employment and clinical screening look for a fixed set of substances: amphetamines, cannabinoids, cocaine, opiates, and phencyclidine on a five-panel, with benzodiazepines, barbiturates, methadone, and a few others added on broader panels. Kratom does not appear on any of these. Its alkaloids are structurally distinct enough from classical opioids that the antibody-based immunoassays used for routine screens simply do not react to them. If a lab wants to find kratom, it has to run a separate assay designed to bind mitragynine or its metabolites. The abbreviation KRA flags that this specific add-on has been included.

Testing labs and third-party providers started offering kratom panels in response to a shift in how the substance is used. What was once a niche herbal product has become widely available online and in convenience stores across the United States. Kratom is not federally scheduled, and regulation varies dramatically by state, ranging from outright bans to consumer-protection acts that impose age limits and labeling requirements but keep the product legal.¹ That patchwork means employers, probation officers, pain clinics, and addiction-treatment programs cannot assume their usual drug panels will catch kratom use. They have to request it.

What Kratom Actually Does in the Body

Kratom’s main compounds, mitragynine and 7-hydroxymitragynine, act on opioid receptors in the brain.² At low doses, users often describe stimulant-like effects such as increased energy and alertness. At higher doses, the opioid-receptor activity becomes more pronounced, producing sedation, pain relief, and euphoria. This dual character is why some people use kratom as a self-managed substitute for prescription opioids or as a way to ease withdrawal symptoms, and it is also why testing programs increasingly want to detect it.

The leaves of the kratom tree contain several structurally related alkaloids beyond mitragynine, including mitraciliatine, speciogynine, and speciociliatine. These compounds share the same molecular formula and atomic connectivity but differ in their three-dimensional arrangement.³ That close structural similarity creates headaches for laboratories trying to measure mitragynine precisely, a point that matters when a positive test result has legal or employment consequences.

How Kratom Is Detected on a Urine Test

When a testing program adds the KRA panel, the lab typically starts with an immunoassay-based screening step. Researchers have developed enzyme-linked immunosorbent assays (ELISA) using antibodies that bind to mitragynine in urine, with detection limits around 0.4 micrograms per milliliter.⁴ This screening step is designed to be fast and relatively inexpensive, sorting samples into “presumptive positive” and “negative” categories. A presumptive positive does not mean the result is final; it means the sample warrants a closer look.

Confirmatory testing uses more powerful instrumentation, most commonly liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). This method physically separates mitragynine and its metabolites from everything else in the sample and then identifies them by molecular weight. It is far more specific than an antibody-based screen and can distinguish between the closely related alkaloids that simpler methods tend to lump together. Routine high-resolution mass spectrometry methods have struggled to fully separate mitragynine from its diastereomers speciogynine and speciociliatine, though improved chromatographic methods can resolve them individually when the lab invests the effort.³

Can Kratom Cause a False Positive for Other Drugs?

This is one of the more practically important questions for anyone who uses kratom and faces routine drug screening. The answer is yes, it can happen. A documented case involved a patient whose urine drug screen came back positive for methadone. The patient denied methadone use but later disclosed regular kratom consumption. The false positive was attributed to a kratom metabolite cross-reacting with the methadone immunoassay.²

Immunoassay-based screens work by recognizing molecular shapes, and when a metabolite from one substance happens to share a similar enough shape with the target drug, the antibody cannot tell the difference. Kratom metabolites are not identical to methadone, but at certain concentrations they can fool the assay. This matters because a false positive for methadone on a workplace screen or in an addiction-treatment setting can have serious consequences: job loss, legal violations, or changes to treatment plans. The takeaway is straightforward. If you use kratom and receive an unexpected positive for methadone (or potentially another opioid), request confirmatory testing by mass spectrometry. The confirmatory test can distinguish kratom metabolites from methadone and resolve the discrepancy.

How Kratom Is Metabolized and Why That Affects Detection

Once you consume kratom, your liver enzymes get to work breaking down mitragynine. The dominant enzyme responsible is CYP3A4, with smaller contributions from CYP2D6 and CYP2C9.⁵ The liver produces multiple metabolites, primarily through O-demethylation and oxidation reactions. One key detail: CYP3A4 is responsible for converting mitragynine into 7-hydroxymitragynine, the more potent opioid-active compound that binds opioid receptors with far greater affinity than mitragynine itself.⁶

The most abundant metabolite found in the urine of kratom users is 9-O-demethylmitragynine, which is produced by CYP2C19, CYP3A4, and CYP2D6.⁶ This matters for testing because labs that only look for mitragynine itself may miss cases where the parent compound has already been heavily metabolized. More sophisticated panels also target key metabolites to improve sensitivity.

From a practical standpoint, the involvement of CYP3A4 means that anything else you consume that inhibits or induces this enzyme can change how fast your body clears kratom. Grapefruit juice, certain antifungal medications, and some antibiotics are well-known CYP3A4 inhibitors. Taking these alongside kratom could slow metabolism, potentially keeping mitragynine detectable in your system for longer and raising the effective dose of 7-hydroxymitragynine your body produces. Conversely, CYP3A4 inducers could speed clearance.

How Long Does Kratom Stay Detectable?

This is the question most people are really asking when they search for information about KRA on a drug test. Unfortunately, the published research has not established a clean, universally agreed-upon detection window the way it has for, say, cannabis or cocaine. Mitragynine’s elimination half-life has been estimated in the range of roughly one day in some pharmacokinetic studies, which would suggest that urine levels drop below detectable thresholds within a few days for occasional users. Heavy, chronic users likely maintain detectable levels for longer, as the compound accumulates in tissues over time.

Blood testing adds another dimension. A study examining mitragynine stability in blood samples stored under common laboratory conditions tracked concentrations over 30 days in different collection tube types, finding that the compound remained measurable throughout the storage period.⁷ That is relevant for forensic and clinical scenarios where blood samples are collected and then sit in a lab before analysis. Mitragynine does not degrade quickly in stored blood, so a positive finding in blood is unlikely to be an artifact of sample handling.

Hair testing pushes the detection window much further. Researchers have validated an LC-MS/MS method for detecting both mitragynine and 7-hydroxymitragynine in hair, successfully identifying kratom use in authentic samples from suspected users.⁸ Hair testing can typically reveal substance use going back months rather than days, though it is more expensive and less commonly ordered outside of forensic or research contexts.

Who Is Ordering KRA Tests and Why

Most standard pre-employment drug screens do not include kratom. If you are applying for a typical office job and taking a standard panel, KRA will not appear. The settings where kratom testing is more common include:

Pain management clinics: Doctors monitoring patients on opioid prescriptions may want to know whether a patient is supplementing with kratom, which could interact with prescribed medications.
Substance abuse treatment programs: Programs treating opioid use disorder sometimes add kratom panels because patients may use it as an undisclosed substitute or alongside medications like buprenorphine or methadone.
Probation and parole: Some jurisdictions, particularly those in states where kratom is banned, include it in court-ordered drug testing.
Military and federal positions: Certain federal agencies and military branches have policies against kratom use and may test for it specifically.
Forensic and postmortem investigations: Coroners and medical examiners may order kratom testing when investigating overdose deaths, as the combination of kratom with fentanyl or other opioids appears to increase the risk of a fatal outcome.⁹

If you are unsure whether a drug test you are facing includes kratom, you can usually ask the administering entity or the lab which specific panels are being run. The abbreviation KRA on the requisition form or results sheet is the giveaway.

The Adulteration Problem With Commercial Kratom Products

One complication that makes kratom testing more fraught than it might seem is the quality of the product itself. Analysis of commercially available kratom products has found that some contain concentrations of 7-hydroxymitragynine that are substantially higher than what occurs naturally in raw kratom leaves.¹⁰ Since 7-hydroxymitragynine is the more potent opioid-receptor agonist, elevated levels suggest that some manufacturers are fortifying their products, either by adding synthetic 7-hydroxymitragynine or by concentrating it during extraction.

This matters for drug testing in a couple of ways. First, if you are using what you believe is a mild, low-dose kratom product, you may actually be consuming significantly more of the potent alkaloid than you think. Your test results could reflect higher metabolite levels than your reported dose would predict, which may raise questions in a clinical or legal setting. Second, adulteration makes it harder for researchers and labs to establish standardized detection thresholds, because the chemical profile of “kratom” varies wildly from product to product. A test calibrated against natural leaf material might behave differently when faced with a heavily fortified extract.

Kratom and Polysubstance Risk in Forensic Testing

The forensic context for KRA testing is grimmer than the employment or clinical one. Postmortem toxicology reports have revealed that kratom frequently appears alongside other substances in overdose deaths, particularly fentanyl and other synthetic opioids. The combined use of kratom with opioids like fentanyl appears to increase the risk of a fatal overdose, and the risk may also extend to combinations with benzodiazepines and psychiatric medications.⁹

Determining causation in these cases is difficult. When a person dies with fentanyl, kratom, a benzodiazepine, and an antidepressant all present, teasing out which substance contributed most to respiratory depression or cardiac arrest is complicated. But the pattern is concerning enough that medical examiners now routinely request kratom testing when the circumstances suggest possible opioid involvement. This is one reason the analytical methods keep improving, because forensic and medico-legal professionals need precise, defensible measurements for courtroom and regulatory purposes.³

What to Do If KRA Shows Up on Your Results

If you see “KRA” on a drug test requisition form, it simply means kratom is being screened for. If you see a positive KRA result and you have been using kratom, the result is probably accurate. If you have not used kratom and receive a positive result, the first step is to request confirmatory testing by LC-MS/MS, which can rule out cross-reactivity from other substances or metabolites.

It is worth knowing that a positive KRA result does not automatically mean you have done something illegal. Kratom is legal in most states, though a handful have banned it and others restrict it to adults over a certain age. The consequences of a positive KRA result depend entirely on the context: a state where kratom is banned, a probation agreement that prohibits it, an employer policy that lists it as a disqualifying substance, or a treatment program where undisclosed use violates the terms of care. In states where kratom is legal and your employer has no policy against it, a positive KRA result may carry no consequences at all.

That said, the regulatory landscape is shifting. More states are considering consumer protection legislation, and some agencies have explored federal scheduling. The fact that labs now offer KRA as a standard add-on panel reflects a broader trend of kratom moving from an unmonitored herbal product toward something that institutions want to track. Whether you are a kratom user, a clinician, or someone who just saw three unfamiliar letters on a lab report, understanding what KRA means puts you in a better position to interpret the result and respond appropriately.

1
PubMed Central. Association between state-level kratom regulations and poison center-reported severe medical outcomes and healthcare use: A United States national analysis
2
American Journal of Clinical Pathology. A Kratom Metabolite Causes False Positive Urine Drug Screening Results for Methadone
3
Europe PMC. Drug testing for mitragynine and kratom: Analytical challenges and medico-legal considerations
4
ACS Omega. Development of Methyl Ester Antibody-Based Competitive Indirect ELISA for Quantitative Detection of Mitragynine in Human Urine
5
PubMed. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)
6
Journal of Analytical Toxicology. CYP450-Mediated Metabolism of Mitragynine and Investigation of Metabolites in Human Urine
7
Chulalongkorn Medical Journal. Comparison of mitragynine stability in human blood in common blood collection tubes
8
PubMed. LC-MS-MS method for mitragynine and 7-hydroxymitragynine in hair and its application in authentic hair samples of suspected kratom abusers
9
PubMed Central. Presence of kratom in opioid overdose deaths: findings from coroner postmortem toxicological report
10
PubMed Central. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine